Europe
The fixed-dose combination was being evaluated in adults with intermediate and high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Brandicourt, who has helmed Sanofi since 2015, will retire from his CEO role this fall. Sanofi has a rule that its CEO cannot be over the age of 65.
Phase III SALAMANDER Trial of Rexgenero’s REX-001 Open and Recruiting
Adocia announces the initiation of a Phase 1b study of ADO09, a ready-to-use, fixed ratio co-formulation of pramlintide, the only FDA-approved analog of amylin, and A21G human insulin analog, a rapid-acting insulin that is known to be the main circulating metabolite of insulin glargine.
LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug research and development, announced the deployment of a research platform focused exclusively on its gut microbiome activities and more precisely on analysis of the therapeutic properties of christensenella.
Novartis announced = new early stage histology data in kidney transplantation, suggesting that with investigational compound iscalimab (CFZ533) it may be possible to prolong the durability of transplanted kidneys as well as to potentially improve long-term outcomes for kidney transplant patients
Pharma and biotech companies strengthen their executive and leadership teams with new appointments.
Here are some of the top research stories that happened around the industry this week.
Typically, fewer than half of kidney transplants last 10 years. As a result, durability is definitely a significant unmet need for patients who have had a transplant or are waiting to receive one.
During an interim analysis of ELEVATE-TN data, AstraZeneca said Calquence met primary endpoints in patients with previously untreated CLL.
PRESS RELEASES